- Year 2014
- Sant Joan Despí Moisès Broggi Hospital
Prospective, multicenter, randomized, open-label, 12-week study to evaluate the efficacy and safety of glycopyrronium (50 micrograms 1 v/d) or the fixed-dose combination of indacaterol maleate and glycopyrronium bromide (110/50 micrograms 1 v/d) in the symptoms and health status of patients with moderate chronic obstructive disease (COPD) who change from standard treatment for COPD,